On June 22, the NMPA official website showed that Eli Lilly’s Category 1 new drug Imlunestrant Tablets have been approved for marketing in China, with the following indications: as monotherapy for adult patients with estrogen receptor (ER)-positive, human epidermal growth…
On June 22, the NMPA official website showed that the Category 1 new drug Peceleganan , filed by Protelight Pharma, was approved for marketing in China. The approved indication is for the treatment of superficial secondary wound infections, including those…
On June 22, Johnson & Johnson announced that its innovative therapeutic drug Zebeka® (niraparib and abiraterone acetate tablets) has received official approval from the National Medical Products Administration (NMPA) for use in combination with prednisone or prednisolone for the treatment…
On June 22, Antengene announced that it has entered into an exclusive license agreement with K2 Therapeutics for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) in development for solid tumors. The company also granted K2 an…
On June 15, BioMap and Harbour BioMed (stock code: 02142.HK) jointly announced a multi-dimensional, long-term strategic partnership to collaborate on the AI-driven discovery and development of complex biologics. The collaboration aims to systematically break through key bottlenecks in next-generation therapy R&D and…
On June 16, Everest Medicines announced that it has entered into an exclusive commercialization licensing agreement with Dimerix Limited, obtaining the rights for clinical development and commercialization of DMX-200 in Greater China, South Korea, and certain Southeast Asian countries (including…
On June 16 local time, neuroscience company 4E Therapeutics, Inc. announced that it has been acquired by Eli Lilly and Company. 4E is dedicated to developing next-generation non-opioid therapies for chronic pain and is currently advancing a pipeline of oral…
On June 15 local time, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental Biologics License Application (sBLA) submitted by its rare disease unit, Alexion, for Ultomiris (ravulizumab) for the…
On June 19 local time, Sanofi announced that the Japanese Ministry of Health, Labour and Welfare has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) in combination with approved standard-of-care regimens for the treatment of multiple myeloma (MM). The approved…
On June 17 local time, GSK and Spero Therapeutics jointly announced that the U.S. Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil), an oral antibiotic, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adults…